Considerations regarding an updated meta-analysis of the optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer

被引：0
|
作者：
Pang, Huayang [1 ,2 ]
Yan, Menghua [1 ]
Chen, Lihui [1 ]
Zhao, Zhou [1 ,2 ]
Li, Wei [1 ]
Zhang, Shouru [1 ]
Sun, Hao [1 ]
机构：
[1] Chongqing Univ Canc Hosp, Dept Gastrointestinal Canc Ctr, Chongqing 400030, Peoples R China
[2] Chongqing Univ Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF SURGERY | 2024年 / 110卷 / 07期
关键词：
FLUOROPYRIMIDINE; THERAPY;
D O I：
10.1097/JS9.0000000000001350
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：4431 / 4432
页数：2
相关论文
共 50 条
  • [31] Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer
    Akagunduz, Baran
    Guven, Deniz Can
    Ozer, Muhammet
    Okten, Ilker Nihat
    Atag, Elif
    Unek, Ilkay Tugba
    Tatli, Ali Murat
    Karaoglu, Aziz
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (02)
  • [32] Cochrane systematic review and meta-analysis of adjuvant chemotherapy for stage II colon cancer
    Meyers, Brandon Matthew
    Al-Shamsi, Humaid Obaid
    Figueredo, Alvaro Tell
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Pharmacogenetic predictors of adverse events in stage II-III colon cancer (CC) patients treated with oxaliplatin and fluoropyrimidines-based adjuvant chemotherapy (CT): A GEMCAD study
    Custodio, Ana
    Moreno, Juan
    Aparicio, Jorge
    Gallego Plazas, Javier
    Fernandez-Martos, Carlos
    Yaya, Ricardo
    Calatrava, Ana M.
    Maurel, Juan
    Burgos, Emilio
    Tejerina, Eva
    Barriuso, Jorge
    Moreno, Victor
    Martinez Marin, Virginia
    De Castro, Javier
    Lamarca, Angela
    Lapunzina, Pablo
    Madero, Rosario
    Cejas, Paloma
    Feliu, Jaime
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
    Custodio, Ana
    Moreno-Rubio, Juan
    Aparicio, Jorge
    Gallego-Plazas, Javier
    Yaya, Ricardo
    Maurel, Joan
    Rodriguez-Salas, Nuria
    Burgos, Emilio
    Ramos, David
    Calatrava, Ana
    Andrada, Encarna
    Diaz-Lopez, Esther
    Sanchez, Antonio
    Madero, Rosario
    Cejas, Paloma
    Feliu, Jaime
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (09) : 2226 - 2237
  • [35] The association of comorbidities with administration of adjuvant chemotherapy in stage III colon cancer patients: a systematic review and meta-analysis
    Boakye, Daniel
    Nagrini, Rajini
    Ahrens, Wolfgang
    Haug, Ulrike
    Guenther, Kathrin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [36] Real-world tolerance and outcomes to oxaliplatin-based adjuvant chemotherapy for stage III colon cancer - Does dose intensity matter?
    Yoon, Robert
    Wilkinson, Kate
    Gabriel, Gabriel
    Kaadan, Nasreen
    Roberts, Tara
    Lim, Stephanie
    Ray, Asghari
    Lee, Cheok Soon
    Chua, Wei
    Ng, Weng
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 132 - 133
  • [37] Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
    Shi, Qian
    Sobrero, Alberto F.
    Shields, Anthony Frank
    Yoshino, Takayuki
    Paul, James
    Taieb, Julien
    Sougklakos, Ioannis
    Kerr, Rachel
    Labianca, Roberto
    Meyerhardt, Jeffrey A.
    Bonnetain, Franck
    Watanabe, Toshiaki
    Boukovinas, Ioannis
    Renfro, Lindsay A.
    Grothey, Axel
    Niedzwiecki, Donna
    Torri, Valter
    Andre, Thierry
    Sargent, Daniel J.
    Iveson, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] A comparison of oxaliplatin-based adjuvant chemotherapy versus improved nodal sampling for stage II colon cancer: Cost-effectiveness and survival
    Chen, SL
    Sim, MS
    Bilchik, AJ
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 41 - 42
  • [39] Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
    Hu, Huabin
    Wu, Zehua
    Wang, Chao
    Huang, Yan
    Zhang, Jianwei
    Cai, Yue
    Xie, Xiaoyu
    Li, Jianxia
    Shen, Cailu
    Li, Weiwei
    Ling, Jiayu
    Xu, Xuehu
    Deng, Yanhong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [40] ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
    P Li
    Y J Fang
    F Li
    Q J Ou
    G Chen
    G Ma
    British Journal of Cancer, 2013, 108 : 1238 - 1244
12345